glp 1 vs gip Science Behind and Glucagon Receptor Agonists for Obesity Research | News & Announcements Dual GIP/GLP-1 receptor agonists: New

Starting in mid-2026, Medicare will begin covering these drugs for select patient groups and state Medicaid programs have the option to adopt similar coverage at these discounted rates

They operate through distinct neurological and metabolic pathways

Learn how GLP-1 receptor agonists help patients with type 2 diabetes and obesity manage blood sugar, lose weight, and protect heart health.

Results show broad benefits with a reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimers disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions

SUPPORTS BODY COMPOSITION: Helps support a balanced approach to body composition by maintaining lean muscle when paired with diet and exercise